New Delhi, Apr 5 (PTI) Aurobindo Pharma on Friday said the US health regulator has issued three observations after inspecting the Andhra Pradesh-based manufacturing unit of its subsidiary.

The US Food and Drug Administration (USFDA) inspected the new injectable facility of Eugia Steriles, a step-down subsidiary of the company, situated in Anakapalli district of Andhra Pradesh, from March 28 to April 5, 2024, the drug firm said in a regulatory filing.

Also Read | BJP Foundation Day 2024 Date: Know the History and Significance of BJP Sthapna Diwas That Celebrates the Formation of the Bharatiya Janata Party.

The inspection closed with three observations, it added.

The observations are procedural in nature and will be responded to within the stipulated time, Aurobindo Pharma said.

Also Read | AMC Raising Day 2024: Army Medical Corps Celebrates 260th Raising Day as They Live Up To The Corps Motto.

Shares of the company on Friday ended 0.02 per cent lower at Rs 1,123.75 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)